Male Breast Cancer and Dysfunction in Neurotransmitter Signaling

Male breast cancer (MBC), though less prevalent than female breast cancer, carries a distinct set of diagnostic, treatment, and survivorship challenges that extend beyond tumor control alone. Increasing clinical attention is being directed toward the neurological and neuromuscular consequences of cancer and cancer therapies, including chemotherapy-induced peripheral neuropathy, treatment-related deconditioning, chronic pain syndromes, fatigue, and loss of functional mobility. These complications reflect not only structural nerve injury, but disruptions in neurotransmitter signaling, microvascular integrity, inflammatory balance, and neuromuscular recruitment patterns.

Neurotransmitters govern the chemical language of nerve-to-muscle and nerve-to-organ communication, shaping sensation, movement, pain perception, autonomic regulation, and recovery capacity. In oncology populations, neurotoxic therapies, metabolic stress, and inflammatory burden can impair these signaling pathways, contributing to numbness, weakness, gait instability, and reduced quality of life. For male breast cancer patients—who already face diagnostic delays and care disparities—neuropathy and neuromuscular dysfunction may remain under-recognized and under-monitored.

This article examines the role of neurotransmitter signaling in neuropathy, the neurovascular mechanisms underlying treatment-related nerve injury, and the emerging role of non-invasive neuromuscular activation strategies within an imaging-guided, evidence-based model of supportive care for men navigating breast cancer diagnosis, treatment, and recovery.

How Chemical Signaling Shapes Pain, Movement, and Recovery
By: Lennard M. Goetze, Ed.D  | Polina Dembe-Petaludis, Ph.D  | Edited by: Daniel Root

Neurotransmitters are the chemical messengers of the nervous system, responsible for transmitting signals between neurons, muscles, glands, and organs. Every movement, sensation, thought, and autonomic function depends on their precise release, reception, and clearance. Disruption in neurotransmitter signaling contributes to neurological disorders, chronic pain syndromes, neuropathy, muscular atrophy, fatigue syndromes, and impaired neuromuscular coordination.

In clinical and rehabilitation medicine, growing attention has been placed on technologies that interface with the nervous system—such as Electrical Muscle Stimulation (EMS)—to support neuromuscular recruitment, circulation, pain modulation, and functional recovery. Understanding how neurotransmitters operate at the synaptic and neuromuscular junction level provides a scientific foundation for evaluating how such technologies may assist recovery, movement retraining, and symptom management in patients with neuropathy, cancer treatment–related nerve damage, metabolic disorders, and inflammatory conditions.

This review examines what neurotransmitters are, how they relate to neuropathy, how they affect the body, whether they “die” or become dormant, and how neuromuscular technologies such as EMS interact with neurotransmitter signaling to restore functional activity.

Do Neurotransmitters Die or Become Dormant?

Neurotransmitters themselves do not “die.” They are synthesized, released, recycled, and degraded in continuous cycles. What can deteriorate is:

·        The neuron producing the neurotransmitter

·        The synapse’s structural integrity

·        The receptor’s responsiveness

·        The metabolic environment needed to sustain neurotransmitter production

In neuropathy and neurodegenerative conditions, signaling pathways may become functionally “dormant” due to reduced neural firing, impaired circulation, mitochondrial dysfunction, oxidative stress, or inflammatory injury. This creates a state where nerves and muscles exist anatomically but are under-stimulated and under-recruited.

This dormant-like state is reversible in some cases, particularly when neural pathways remain intact but inactive. Rehabilitation strategies aim to re-engage these pathways through mechanical loading, sensory input, neuromuscular activation, circulation enhancement, and metabolic support.

Conclusion

Neurotransmitters represent the biochemical language of movement, sensation, and repair. In neuropathy and chronic disease states, neurotransmitter signaling is disrupted not because the system “dies,” but because metabolic, vascular, and inflammatory conditions impair neural function. Technologies such as Electrical Muscle Stimulation operate within this biological framework by activating neuromuscular circuits, preserving synaptic signaling, and supporting rehabilitation in patients with partial neural compromise.

When integrated into a clinically guided, evidence-based model—including imaging validation, metabolic support, circulation enhancement, and movement retraining—neuromuscular stimulation technologies serve as functional tools for preserving performance, restoring activity, and supporting recovery. The future of neurorehabilitation lies not in isolated devices, but in image-guided, physiologically grounded protocols that respect the complex chemical–electrical language of the nervous system.

References:

1) Pieber, K., Herceg, M., & Paternostro-Sluga, T. (2010). Electrotherapy for the treatment of painful diabetic peripheral neuropathy: A review. Journal of Rehabilitation Medicine, 42(4), 289–295. doi:10.2340/16501977-0554. (2) Weintraub, M. I., Herrmann, D. N., Smith, A. G., Backonja, M. M., & Cole, S. P. (2009). Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: A randomized controlled trial. Archives of Physical Medicine and Rehabilitation, 90(7), 1102–1109.

2) Transcutaneous electrical nerve stimulation. (2026). In Encyclopedia of Physical Therapy. Retrieved from https://en.wikipedia.org/wiki/Transcutaneous_electrical_nerve_stimulation

3) Pulsed electromagnetic field therapy. (n.d.). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Pulsed_electromagnetic_field_therapy

4) Peripheral neuropathy. (n.d.). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Peripheral_neuropathy

5) Battecha, K., et al. (2017). Efficacy of pulsed electromagnetic field on diabetic peripheral neuropathy. Bulletin of Faculty of Physical Therapy, 22, 9–14.

6) Graak, V., Chaudhary, S., Sandhu, B. S., & others. (2009). Evaluation of the efficacy of pulsed electromagnetic field in the management of patients with diabetic polyneuropathy. PMCID: PMC2812751.

7) Cochrane Database (2017). Transcutaneous electrical nerve stimulation for neuropathic pain. (This is a systematic review you can cite.)

Disclaimer:
This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content reflects current scientific understanding and clinical perspectives but is not a substitute for professional medical evaluation or individualized care. Readers should consult qualified healthcare providers regarding any medical condition, diagnosis, or treatment decisions.